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Abstract Accumulation of hyperphosphorylated, ubiqui-
tinated and N-terminally truncated TAR DNA-binding pro-
tein (TDP-43) is the pathological hallmark lesion in most
familial and sporadic forms of FTLD-U and ALS, which
can be subsumed as TDP-43 proteinopathies. In order to get
more insight into the role of abnormal phosphorylation in
the disease process, the identiWcation of speciWc phosphor-
ylation sites and the generation of phosphorylation-speciWc
antibodies are mandatory. Here, we developed and charac-
terized novel rat monoclonal antibodies (1D3 and 7A9)
raised against phosphorylated S409/410 of TDP-43. These
antibodies were used to study the presence of S409/410
phosphorylation by immunohistochemistry and biochemi-
cal analysis in a large series of 64 FTLD-U cases with or
without motor neuron disease including familial cases with
mutations in progranulin (n = 5), valosin-containing protein
(n = 4) and linkage to chromosome 9p (n = 4), 18 ALS
cases as well as other neurodegenerative diseases with con-
comitant TDP-43 pathology (n = 5). Our data demonstrate
that phosphorylation of S409/410 of TDP-43 is a highly
consistent feature in pathologic inclusions in the whole
spectrum of sporadic and familial forms of TDP-43 protein-
opathies. Physiological nuclear TDP-43 was not detectable
with these mAbs by immunohistochemistry and by immu-
noblot analyses. While the accumulation of phosphorylated
C-terminal fragments was a robust Wnding in the cortical
brain regions of FTLD-U and ALS, usually being much
more abundant than the phosphorylated full-length TDP-43
band, spinal cord samples revealed a predominance of full-
length TDP-43 over C-terminal fragments. This argues for
a distinct TDP-43 species composition in inclusions in
cortical versus spinal cord cells. Overall, these mAbs are
powerful tools for the highly speciWc detection of disease-
associated abnormal TDP-43 species and will be extremely
useful for the neuropathological routine diagnostics of
TDP-43 proteinopathies and for the investigation of emerg-
ing cellular and animal models for TDP-43 proteinopathies.
Introduction
After its initial identiWcation in 2006 [28], numerous stud-
ies have now conWrmed that abnormal neuronal and glial
inclusions composed of the TAR DNA-binding protein 43
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several neurodegenerative disorders, which can be sub-
sumed under the term TDP-43 proteinopathies [20, 26].
This includes sporadic frontotemporal lobar degeneration
with tau-negative and ubiquitin-positive inclusions (FTLD-
U) with and without motor neuron disease (MND), familial
forms of FTLD-U with mutations in the progranulin gene
(GRN), valosin-containing protein (VCP) and linkage to
chromosome 9p, as well as most forms of amyotrophic lat-
eral sclerosis (ALS) with the exception of familial ALS
with SOD-1 mutations [7, 9, 10, 23, 28]. In addition, con-
comitant TDP-43 pathology is present in a subset of other
neurodegenerative diseases, such as Alzheimer’s disease
(AD) [1, 35], corticobasal degeneration (CBD) [35], Lewy-
body dementia (LBD) [25] and parkinsonism-dementia
complex of Guam [12, 14].
TDP-43 is a highly conserved 414-amino acid nuclear
protein Wrst cloned as a protein capable of binding to the
transactive response DNA element of human immunodeW-
ciency virus type 1 and later identiWed as part of a complex
involved in splicing of the cystic Wbrosis transmembrane
conductance regulator gene [5, 30]. TDP-43 contains two
RNA recognition motifs and a glycine-rich C-terminal
region. Described functions include involvement in tran-
scription regulation, exon skipping and a role as scaVold for
nuclear bodies through an interaction with survival motor
neuron protein [4, 39]. Pathological TDP-43 is abnormally
phosphorylated, ubiquitinated, and cleaved to generate car-
boxy-terminal fragments (CTFs) in aVected brain regions in
TDP-43 proteinopathies [28]. Additionally, while TDP-43
is predominantly found in the nucleus under physiologic
conditions, the nuclear staining is dramatically reduced in
inclusion bearing cells [28] leading to the hypothesis that
alterations of the nuclear import of TDP-43 might contrib-
ute to disease pathogenesis. A direct link between TDP-43
dysfunction and neurodegeneration was further provided
recently by the identiWcation of several mutations in the
TARDBP gene encoding for TDP-43 in ALS [13, 18, 19,
32, 34, 36]. However, the underlying mechanisms leading
to TDP-43 accumulation and the consequences of TARDBP
mutations are still unclear. Due to the fact that TDP-43 is
hyperphosphorylated in disease process and that several
TARDBP mutations introduce either new potential
phosphorylation sites or are predicted to increase phosphor-
ylation of adjacent serine residues, alterations in phosphor-
ylation/dephosphorylation of TDP-43 might play a crucial
role in the pathogenesis of TDP-43 proteinopathies. There-
fore, further insight of TDP-43 phosphorylation in physio-
logical and disease conditions is essential and might help to
elucidate the pathologic process in TDP-proteinopathies.
TDP-43 has 41 serine, 15 threonine and 8 tyrosine residues,
which might act as potential phosphorylation sites. To iden-
tify sites actually phosphorylated in TDP-43 we started to
generate antibodies raised against diVerent phosphopep-
tides of TDP-43. While this work was in preparation, two
publications using a similar approach have demonstrated
that TDP-43 becomes abnormally phosphorylated at S379,
403, 404, 409, and 410 in small numbers of cases of spo-
radic FTLD-U, familial FTLD-U with GRN mutation and
ALS [15, 17].
In this study, we describe the generation and character-
ization of novel rat monoclonal antibodies (mAbs) raised
against phosphorylated S409/410 (pS409/410) of TDP-43,
which allowed the highly sensitive and speciWc labeling of
disease-associated TDP-43 species, but not physiologic
TDP-43 by immunohistochemistry and immunoblot analy-
sis. We extend our investigation of pS409/410 to a much
larger series of cases covering the whole spectrum of TDP-
43 proteinopathies (n = 87), including sporadic FTLD-U,
familial FTLD-U with mutations in GRN, VCP and linkage
to chromosome 9, ALS and tauopathies with concomitant
TDP-43 pathology. Our Wndings demonstrate that phos-
phorylation of S409/410 of TDP-43 is a highly consistent
feature of abnormal inclusions in the whole spectrum of
TDP-43 proteinopathies and that these novel mAbs are
powerful tools for the routine diagnostics of TDP-43
proteinopathies and for further analysis of cell-culture and
animal models for TDP-43 proteinopathies.
Materials and methods
Generation of monoclonal antibodies
The phosphopeptide pS409/410 (SMDSKS(p)S(p)GWG),
corresponding to amino acid residues 404–413 of human
TDP-43 and phosphorylation of serine residues 409/410,
was synthesised and coupled to bovine serum albumin or
ovalbumin (OVA) by cysteine linkage at the amino-termi-
nus (Peptide Specialty Laboratories GmbH, Heidelberg,
Germany). Lou/c rats were immunized with subcutaneously
and intraperitoneally with a mixture of 50 g OVA-coupled
pS409/410 peptide, 5 nmol CpG 2006 oligonucleotide (Tib
Molbiol, Berlin, Germany), 500 l PBS and 500 l incom-
plete Freund’s adjuvance. After a 6 weeks interval, rats
were boosted with 50 g OVA-coupled pS409/410 peptide
in PBS. Hyperimmune spleen cells were fused with the
mouse myeloma cell line P3X63Ag8.653 using standard
procedures. Supernatants were Wrst screened in a diVeren-
tial enzyme-linked immunosorbent assay (ELISA) with the
phospho- and corresponding non-phosphopeptide to select
for phosphorylation-speciWc mAbs. IdentiWed and further
characterized phosphospeciWc mAbs clone 1D3 and clone
7A9 are both rat IgG2a. To investigate whether both phos-
phorylation sites were necessary for antibody binding of 1D3
and 7A9, additional phosphopeptides with either pS409123
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synthesized, coupled to OVA and analyzed by ELISA.
Phosphopeptides for other potentially phosphorylated
serine residues (S91/92, 183, 242, 254, 266, and 273) of
TDP-43 used for antibody generation are listed in supple-
mentary Table 1. These sites were chosen either due to pub-
lished data as for pS91/92 [29] or due to a high predictive
value for being phosphorylated by Netphos2 search (http://
www.cbs.dtu.dk/services/NetPhos). While phospho-spe-
ciWc supernatants were identiWed by ELISA assay for these
peptides, none of them revealed any speciWc immunoreac-
tivity by subsequent immunohistochemistry and immuno-
blot analysis of FTLD-U brains. However, these negative
data do not necessarily indicate that these sites are not
phosphorylated in TDP-43.
Case selection
The following cases from the Center for Neuropathology
and Prion Research (Munich, Germany), Center for Neuro-
degenerative Disease Research (Philadelphia, USA) and
Department of Neuropathology (Aalborg, Denmark) were
included in the study: (1) familial FTLD-U with linkage to
chrom 9p (n = 4), GRN (n = 5), and VCP (n = 4) mutations;
(2) FTLD-U either sporadic or familial with unknown
genetic defect (subtype 1 (n = 14); subtype 2 (n = 19); sub-
type 3 (n = 18) according to [33]); (3) ALS (n = 18); (4)
Tauopathies with concomitant TDP-43 pathology
[AD + TDP-43 (n = 3); CBD + TDP-43 (n = 2)]. Cases of
FTLD-U had a clinical diagnosis of the FTD spectrum
(behavioural variant of FTD, progressive non-Xuent apha-
sia, semantic dementia) with or without concomitant MND.
Cases of ALS had clinical signs of MND with some of
them developing cognitive changes only late in disease pro-
cess. In addition, healthy controls (n = 5), AD without
TDP-43 pathology (n = 5), CBD without TDP-43 (n = 4)
and TDP-43 negative FTLD-U cases (n = 9) [31] were
included. Demographic, clinical and neuropathological data
are summarized in Table 1.
Immunohistochemistry
Immunohistochemistry was performed with mAB 1D3 and
7A9 as well as phosphorylation-independent polyclonal
TDP-43 (ProteinTech Group, Chicago, IL, USA; dilution
1:2000) and polyclonal C-tTDP-43 raised against amino
acids 394–414 of human TDP-43 [16].
Tissue was either formalin-Wxed with Wxation-times
ranging from 1 day up to 4 years or ethanol-Wxed (1 day)
and paraYn-embedded. Antigen retrieval was performed by
boiling the sections in 10 mmol/L citrate buVer (pH 6.0) in
a microwave oven. Immunohistochemistry was performed
using biotinylated secondary antibodies and the avidin-biotin
complex detection system (Vector Laboratories, Burlin-
game, CA, USA) with 3,3-diaminobenzidine as chromogen.
Double-labeling immunoXuorescence was performed using
Alexa Fluor 488 and 594 conjugated secondary antibodies
(anti-rat IgG and anti-rabbit IgG, Molecular Probes,
Eugene, OR, USA). 4-6-diamidino-2-phenylindol (DAPI)
(Vector Laboratories, Burlingame, CA, USA) was used for
nuclear counterstaining.
Biochemical fractionation and immunoblot analysis
Frozen brain tissue from diVerent TDP-43 proteinopathies
(n = 66) was used for the sequential extraction of proteins
with buVers of increasing stringency, as described [28].
BrieXy, gray matter was extracted at 5 mL/g (v/w) with
low-salt buVer (10 mmol/L Tris, pH 7.5, 5 mmol/L EDTA,
1 mmol/L dithiothreitol, 10% sucrose, and a cocktail of
protease inhibitors), high-salt-Triton X buVer (low-salt
buVer + 1% Triton X-100 + 0.5 mol/L NaCl), myelin Xota-
tion buVer (Triton X buVer containing 30% sucrose), and
Sarkosyl buVer (low-salt buVer + 1% N-lauroyl-sarcosine +
0.5 mol/L NaCl). The detergent-insoluble material was then
extracted in 0.25 mL/g of urea buVer (7 mol/L urea, 2 mol/
L thiourea, 4% 3-[(3-cholamidopropyl)dimethylammonio]-
1-propanesulfonate, 30 mmol/L Tris, pH 8.5).
Where indicated, TDP-43 was dephosphorylated by dial-
ysis (50 mmol/L Tris and 0.2 mmol/L EDTA, pH 8.0) and
treated with Escherichia coli alkaline phosphatase (Sigma-
Aldrich, St. Lois, MO) for 2 h at 56°C. For immunoblot
analysis, equal volumes of urea fractions were resolved by
either 10 or 15% Tris–glycine SDS-PAGE, transferred to
polyvinylidene diXuoride membranes (Millipore, Billerica,
MA, USA) and probed with C-tTDP-43 and novel mAbs.
Primary antibodies were either detected with alkaline
phosphatase-conjugated anti-rabbit or anti-rat IgG (Dako),
developed with CPD star (Roche Molecular Biochemicals,
Mannheim, Germany) and visualized using the Chemolu-
mineszenz Imager CHEMOCAM HR 16 (Intas, Goettingen,
Germany) or with horseradish peroxidase-conjugated anti-
rat or anti-rabbit IgG (Jackson ImmunoReasearch, West
Grove, PA, USA), developed with Renaissance Enhanced
Luminol Reagents (NEN Life Science Product, Inc., Boston,
MA, USA), and visualized using a FujiWlm Intelligent Dark-
box II (Fuji Systems USA, Stamford, CT, USA).
Results
Characterization of novel mAbs
ELISA data using serial dilutions of synthetic phospho- and
non-phosphorylated peptides corresponding to amino acids123
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Case no. Diagnosis Disease 
duration
Age at 
death
Sex Dementia 
(Y/N)
MND 
(Y/N)
Family 
history 
(Y/N)
Mutation/
linkage
Familial FTLD-U with known genetic defect
1 FTLD-U 2 2 61 m N Y Y chrom 9p
2 FTLD-U 2 3 66 f N Y Y chrom 9p
3 FTLD-U 2 2 74 m Y Y Y chrom 9p
4 FTLD-U 2 2 41 f Y Y Y chrom 9p
5 FTLD-U 3 8 69 f Y N Y GRN p.Q337X 
6 FTLD-U 3 5 78 f Y N Y GRN pW304X
7 FTLD-U 3 4 62 f Y N Y GRN p.R418X
8 FTLD-U 3 8 65 m Y N Y GRN p.R493X
9 FTLD-U 3 3 68 f Y N NA GRN pR418X
10 FTLD-U 3 7 76 f Y N Y GRN pA237TfsX5
11 FTLD-U 4 8 70 f Y N Y VCP R155C
12 FTLD-U 4 5 56 f Y N Y VCP R155H
13 FTLD-U 4 6 60 f Y N Y VCP R155H
14 FTLD-U 4 8 60 f Y N Y VCP R155H
Sporadic FTLD-U and familial FTLD-U with unknown genetic defect
15 FTLD-U 1 8 73 m Y N N –
16 FTLD-U 1 NA 52 f Y N N –
17 FTLD-U 1 10 73 m Y N N –
18 FTLD-U 1 2 66 f Y N N –
19 FTLD-U 1 8 58 m Y N N –
20 FTLD-U 1 2 60 m Y N N –
21 FTLD-U 1 28 70 m Y N N –
22 FTLD-U 1 5 63 f Y N NA –
23 FTLD-U 1 7 54 m Y N N –
24 FTLD-U 1 3 92 m Y N N –
25 FTLD-U 1 12 77 m Y N N –
26 FTLD-U 1 5 69 f Y N N –
27 FTLD-U 1 NA 77 f Y N N –
28 FTLD-U 1 6 68 f Y N N –
29 FTLD-U 2 7 57 f Y Y Y –
30 FTLD-U 2 NA 72 m Y N N –
31 FTLD-U 2 1 59 m Y N N –
32 FTLD-U 2 3 42 f Y Y N –
33 FTLD-U 2 2 71 m Y N N –
34 FTLD-U 2 >3 51 m Y N N –
35 FTLD-U 2 9 49 m Y Y N –
36 FTLD-U 2 2 67 m Y Y N –
37 FTLD-U 2 NA 44 m Y Y N –
38 FTLD-U 2 2 47 f Y N N –
39 FTLD-U 2 3 57 m Y N N –
40 FTLD-U 2 6 41 m Y N Y –
41 FTLD-U 2 1 46 m Y N Y –
42 FTLD-U 2 10 76 m Y N N –
43 FTLD-U 2 13 76 f Y Y Y –
44 FTLD-U 2 7 54 f Y N Y –123
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Case no. Diagnosis Disease 
duration
Age at 
death
Sex Dementia 
(Y/N)
MND 
(Y/N)
Family 
history 
(Y/N)
Mutation/
linkage
45 FTLD-U 2 3 57 m Y Y Y –
46 FTLD-U 2 4 61 f Y N Y –
47 FTLD-U 2 10 67 m Y Y Y –
48 FTLD-U 3 NA 78 m Y N Y –
49 FTLD-U 3 2 60 f Y N N –
50 FTLD-U 3 2 37 m Y Y N –
51 FTLD-U 3 1 65 m Y Y N –
52 FTLD-U 3 3 58 f Y N N –
53 FTLD-U 3 3 64 m Y N Y –
54 FTLD-U 3 4 60 f Y N Y –
55 FTLD-U 3 3 72 m Y N N –
56 FTLD-U 3 3 49 f Y Y N –
57 FTLD-U 3 3 75 f Y N N –
58 FTLD-U 3 2 48 m Y Y N –
59 FTLD-U 3 2 53 f Y Y N –
60 FTLD-U 3 3 53 m Y Y NA –
61 FTLD-U 3 3 72 f Y N N –
62 FTLD-U 3 10 77 f Y N NA –
63 FTLD-U 3 4 63 f Y N NA –
64 FTLD-U 3 6 71 m Y N NA –
Amyotrophic lateral sclerosis
65 ALS 2 81 f N Y N –
66 ALS 1 77 f N Y N –
67 ALS 2 51 m N Y N –
68 ALS 1–2 63 m Y (mental retardation) Y N –
69 ALS 3 68 m N Y N –
70 ALS 2 67 m N Y N –
71 ALS 1 76 f N Y N –
72 ALS 5 60 m Y (late in disease course) Y N –
73 ALS 2 68 m N Y N –
74 ALS 2 54 m N Y N –
75 ALS 2 56 f N Y N –
76 ALS 2 61 m N Y N –
77 ALS 1 55 f Y Y N –
78 ALS 2 51 m N Y N –
79 ALS 2 63 m N Y N –
80 ALS 1.5 51 f Y Y N –
81 ALS 1 65 m Y Y N –
82 ALS 5 66 f N Y N –
Other neurodegenerative disorders with concomitant TDP-43 pathology
83 AD + neocortical TDP 15 81 f Y N N –
84 AD + neocortical TDP 4 80 f Y N N –
85 AD + limbic TDP NA 93 f Y N N –
86 CBD + TDP-43 6 56 m Y N N –
87 CBD + TDP-43 3 61 f Y N N –123
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7A9 reacted strongly with the peptide phosphorylated at
both serine residues 409 and 410 (pS409/410), but not with
the non-phosphorylated peptide. A weaker signal was
obtained for phosphopeptides with phosphorylation of
either S409 (pS409) or 410 (pS410), suggesting that mAbs
1D3 and 7A9 have the highest binding aYnity if both serine
residues are phosphorylated.
As a next step, we performed immunoblot and immuno-
histochemical analysis on a selected FTLD-U case (#21,
Table 1) to further characterize these mAbs and to deter-
mine their applicability and usefulness in these assays.
Using the polyclonal phosphorylation-independent anti-
body C-tTDP-43 raised against amino acids 394–414 of
human TDP-43 [16], sarcosyl-insoluble protein fractions
isolated from FTLD-U brains shows a highly characteristic
biochemical pattern in immunoblots with additional bands
»25 kDa, 45 kDa and a high molecular smear in addition to
the physiological TDP-43 »43 kDa (Fig. 1b), as described
previously [28]. In contrast, mAbs 1D3 and 7A9 revealed a
strong labeling of the abnormal TDP-43 species in the
sarcosyl-insoluble protein fractions with no detection of
the physiological TDP-43 band »43 kDa (Fig. 1b). The
phospho-speciWcity of the novel mAbs was further con-
Wrmed by immunoblot analysis of protein samples being
dephosphorylated by alkaline phosphatase treatment, which
completely abolished the immunoreactivity of 1D3 and
7A9 (Fig. 1c). No labeling of TDP-43 was detectable in
RIPA and urea fractions isolated from cell cultures or
mouse brains with mAbs 1D3 and 7A9 (data not shown).
mAbs 1D3 and 7A9 strongly labeled pathological TDP-
43 inclusions in paraYn-embedded tissue as demonstrated
in the dentate granule cells of an FTLD-U case in Fig. 1d.
In contrast to the phosphorylation-independent antibody
C-tTDP-43, no physiological nuclear staining of non-inclu-
sion bearing cells was detectable with 1D3 and 7A9
(Fig. 1d).
In combination with the immunoblot data, these data
demonstrate that these antibodies are highly speciWc tools
for the detection of abnormal pathological TDP-43 species
and that phosphorylation of S409/410 is not present in a
signiWcant amount in the physiological state of TDP-43.
Immunohistochemistry of novel mAbs in wide spectrum 
of sporadic and familial forms of TDP-43 proteinopathies
Since the initial characterization of 1D3 and 7A9 by immu-
noblot and IHC showed similar results, detailed analyses of
large numbers of TDP-43 proteinopathies were performed
with mAb 1D3.
1D3 labels all types of abnormal inclusions
previously described with phosphorylation-independent
Table 1 continued
FTLD-U Frontotemporal lobar degeneration with ubiquitin-positive inclusions, ALS amyotrophic lateral sclerosis, aFTLD-U atypical FTLD-U,
AD Alzheimer’s disease, CBD corticobasal degeneration, m male, f female, NA not available
Case no. Diagnosis Disease 
duration
Age at 
death
Sex Dementia 
(Y/N)
MND 
(Y/N)
Family 
history 
(Y/N)
Mutation/
linkage
Neurodegenerative disorders without TDP-43 pathology
88 aFTLD-U 5 33 m Y N N –
89 aFTLD-U 5 46 m Y N N –
90 aFTLD-U NA 49 m Y N N –
91 aFTLD-U 9 48 f Y N N –
92 aFTLD-U 5 40 f Y N N –
93 aFTLD-U 4 50 f Y N N –
94 aFTLD-U 4 59 m Y N N –
95 aFTLD-U 15 54 f Y N N –
96 aFTLD-U 5 41 m Y N N –
97 AD 3 61 f Y N N –
98 AD 14 86 f Y N N –
99 AD 14 76 m Y N N –
100 AD/DLB 11 83 f Y N N –
101 AD 13 81 m Y N N –
102 AD 5 56 f Y N N –
103 CBD 3 76 f Y N N –
104 CBD 3 59 m Y N N –123
Acta Neuropathol (2009) 117:137–149 143TDP-43 antibodies, such as dystrophic neurites (DNs),
neuronal cytoplasmic inclusions (NCI), neuronal intranu-
clear inclusions (NII) and glial cytoplasmic inclusions
(GCIs). Figure 2 shows representative images of 1D3 immu-
noreactivity in the investigated subgroups of TDP-43 pro-
teinopathies, with strong labeling of long DNs in FTLD-U
Fig. 1 Characterization of novel mAbs 1D3 and 7A9. a ELISA per-
formed with serial dilutions of OVA-coupled phospho- and non-phos-
phopeptides corresponding to amino acids 404-413 of human TDP-43
(range 2–250 ng/ml) demonstrating the high speciWcity of mAbs 1D3
and 7A9 for the detection of peptides phosphorylated at S409/410.
b Immunoblot analysis of urea fraction from FTLD-U brain separated
by 10% SDS-PAGE with phosphorylation-independent polyclonal
C-tTDP-43 antibody raised amino acids 394–414 of human TDP-43
and phosphorylation speciWc mAb 1D3. While C-tTDP-43 shows the
physiological TDP-43 band »43 kD (arrow) in addition to the patho-
logic TDP-43 species detected as »25 kDa (*), 45 kDa (**) and high
molecular smear (***), mAb 1D3 and 7A9 speciWcally label only the
abnormal TDP-43 species. c Immunoblot analysis of urea samples
from FTLD-U dephosphorylated by alkaline phosphatase (AP)
treatment show a complete lack of immunoreactivity conWrming
the speciWcity of mAb 1D3 against phosphorylated TDP-43 spe-
cies. d Immunohistochemistry of hippocampus from FTLD-U brain
shows numerous cytoplasmic inclusions as well as nuclear staining of
non-inclusion bearing cells with C-tTDP-43 antibody. In contrast,
mAb 1D3 and 7A9 only reveal the pathologic inclusions but do not
show any nuclear immunoreactivity. Scale bar corresponds to 10 m
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and NCIs, short DNs and NIIs in FTLD-U subtype 3
(Fig. 2c). Chrom 9p linked FTLD-U showed numerous “pre-
inclusions” (Fig. 2d) in addition to compact NCIs. In GRN
mutation cases, there was strong labeling of NCIs, short DNs
and NIIs (Fig. 2e) and numerous NIIs and DNs were detect-
able in VCP mutation cases (Fig. 2f), while in ALS spinal
cord motor neurons showed 1D3- positive round and skein-
like inclusions (Fig. 2 g). TDP-43 pathology can also occur
in combination with other neurodegenerative diseases, such
as AD and CBD, and, as demonstrated in Fig. 2h, i, the TDP-
43 pathology in AD and CBD was also strongly labeled with
1D3. No staining for 1D3 was observed in healthy controls
and TDP-43 negative FTLD-U cases.
Finally, double-labeling immunoXuorescence for 1D3
and phosphorylation-independent TDP-43 showed a com-
plete overlap of labeling of pathologic inclusions (Fig. 3a–
c), including the more granular, cytoplasmic “pre-inclu-
sions” (Fig. 3d–f). While compact neuronal inclusions were
consistently double-labeled by 1D3 and anti-ubiquitin
(Fig. 3g–i), the majority of “pre-inclusions” were only
detectable with 1D3 and not by anti-ubiquitin (Fig. 3j–l).
Overall, these data indicate that abnormal phosphoryla-
tion of S409/410 is present in inclusions in all familial and
sporadic forms of TDP-proteinopathies and that hyper-
phosphorylation at S409/410 precedes ubiquitination.
Biochemical analysis of phosphorylated TDP-43 in wide 
spectrum of TDP-43 proteinopathies
To characterize the abnormal S409/410 phosphorylation of
TDP-43 in more detail biochemically, immunoblots were
performed on samples extracted from frozen brain tissue of
cases from the distinct TDP-43 subgroups. A consistent
Wnding in urea fractions extracted from frontal cortex of
sporadic and familial FTLD-U cases was the presence of
abnormal TDP-43 species detectable with mAb 1D3 as a
high molecular smear, a band »45 kDa, and up to 4 bands
»20–25 kDa labeled as 1–4 (Fig. 4a). Since previous
reports on small numbers of FTLD-U cases claimed that
Fig. 2 TDP-43 is phosphorylated at S409/410 in the whole spectrum
of sporadic and familial TDP-43 proteinopathies. Representative
images from abnormal inclusions in the distinct subgroups of TDP-43
proteinopathies stained with 1D3 are shown. a sporadic FTLD-U sub-
type 1: long neuritic proWles, b. sporadic FTLD-U subtype 2: cytoplas-
mic inclusions, c sporadic FTLD-U subtype 3: cytoplasmic inclusions
and small neuritic proWles, d familial FTLD-U linked to chromosome
9: more diVuse cytoplasmic staining (“pre-inclusions”), e familial
FTLD-U with GRN mutation: numerous small neurites and cytoplas-
mic inclusions, f familial FTLD-U with VCP mutation: small neurites
and nuclear inclusions, g sporadic ALS: skein-like inclusions in spinal
motor neurons, h AD with concomitant TDP-43: small neurites and
cytoplasmic inclusions, i CBD with concomitant TDP-43: abundant
white matter pathology. Scale bar corresponds to 50 m123
Acta Neuropathol (2009) 117:137–149 145distinct patterns of C-terminal fragments (CTF) correlate
with FTLD-U subtypes and clinical phenotypes [15, 17],
we performed a detailed analysis of the distinct C-terminal
fragments. The CTFs labeled as 1 and 2 in Fig.4 were the
most prominent bands present in all sporadic and familial
FTLD-U cases although with variable amounts from case to
case. While there was some similarity with previously
described CTF patterns [15, 17], we were not able to delin-
eate a distinct pattern of CTFs correlating with either histo-
logical, genetic or clinico-pathological (e.g. presence of
MND) FTLD-U subtypes.
In ALS cases, the amount of pathological TDP-43 spe-
cies detectable in motor cortex and spinal cord with 1D3 by
immunoblot (Fig. 4b) was more variable and sometimes
hard to detect most likely due to the lower number of inclu-
sions in ALS compared to FTLD-U. While most protein
samples extracted from the motor cortex of ALS showed a
similar banding pattern as seen in FTLD-U, the spinal cord
Fig. 3 Double-label immunoXuorescence. Sections from spinal cord
(a–c, g–i) and motor cortex (d–f, j–l) from an ALS case were either
double-labeled for mAb 1D3 (a, d) and phosphorylation-independent
rTDP (b, e) or 1D3 (g, j) and ubiquitin (h, k). Merged images are
shown in c, f, i and l. 1D3 and rTDP-43 show a complete overlap of
staining of pathologic inclusions, such as skein-like inclusion in motor
neuron (a–c), glial cytoplasmic inclusions (arrow in a–c) as well as
more granular, diVuse cytoplasmic inclusions (“pre-inclusions”) in the
motor cortex (d–f). Note the absence of nuclear staining with 1D3. In
contrast with compact neuronal inclusions which are consistently
double-labeled by 1D3 and anti-ubiquitin (g–i), 1D3-positive “pre-
inclusions” are negative with anti-ubiquitin (j–k). Scale bar corre-
sponds to 20 m123
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>50% of examined cases and only presented with a phos-
phorylated full-length TDP-43 band. This diVerence in
phosphorylated full-length (FL) versus CTFs was further
documented by quantitative analysis of band intensities of
CTFs and FL TDP-43 and calculation of CTF:FL ratios
(Fig. 5). The lowest ratio was obtained for the spinal cord
samples (mean 0.5), while CTF:FL ratio for the examined
cortical brains regions in FTLD-U and ALS ranged from
1.1 (ALS-MCtx) to 3.6 (FTLD-U type3).
Immunoblot analysis of examined cases with concomi-
tant TDP-43 in the context of other neurodegenerative dis-
ease such as CBD and AD, revealed a labeling of abnormal
FL and CTFs, with clear predominance of CTFs (Fig. 4c)
especially in the AD cases. In contrast to FTLD-U cases,
the smallest CTF band (labeled as 1 in Fig. 4a) seems to be
the most intense.
No signal was obtained in AD cases without TDP-43
pathology (Fig. 4c), TDP-43 negative FTLD-U and healthy
controls (data not shown).
Discussion
The abnormal accumulation of TDP-43 is the characteristic
feature in a spectrum of neurodegenerative diseases, including
Fig. 4 Biochemical analysis of S409/410 phosphorylated TDP-43.
a Sarcosyl-insoluble, urea-soluble protein fractions extracted from
frontal cortex from distinct FTLD-U subgroups were separated by
15% SDS-PAGE and immunoblotted with mAb 1D3. The detection of
C-terminal fragments (up to 4 distinct bands labeled as 1–4) between
20 and 25 kDa, phosphorylated full-length TDP-43 band (»45 kD)
and a high molecular smear was present in all tested sporadic and
familial forms of FTLD-U. However, no clear correlation between dis-
tinct banding patterns of C-terminal fragments and FTLD-U subtypes
was detectable. b Urea-samples extracted from motor cortex (MCtx)
and spinal cord (sc) samples of ALS cases and immunoblotted with
1D3. A similar biochemical proWle as for FTLD-U brains was detect-
able in MCtx samples. However, in sc samples the predominant band
detectable was phosphorylated full-length TDP-43. c Urea-samples
extracted from frontal cortex (fc) or hippocampus (hp) from CBD and
AD cases with or without TDP-43 pathology. Note the absence of
immunoreactivity with 1D3 in AD case without TDP-43 pathology
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Acta Neuropathol (2009) 117:137–149 147most forms of familial and sporadic FTLD-U with or with-
out MND and ALS. As is true for proteins accumulating in
other neurodegenerative diseases, such as tau or -synuc-
lein [11, 21], abnormal phosphorylation of TDP-43 has also
been demonstrated to occur in the disease process of TDP-
43 proteinopathies [2, 28]. To learn more about the rele-
vance of abnormal phosphorylation in the pathogenesis of
these conditions, it is essential to identify potential phos-
phorylation sites and to study their functional conse-
quences. Indeed very recently, several phosphorylation
sites (S379, 403, 404, 409, and 410) of TDP-43 have been
identiWed by generating antibodies against predicted phos-
phorylation sites and using these antibodies to analyze
small numbers of sporadic cases of FTLD-U, familial
FTLD-U with GRN mutations and ALS [15, 17]. We used a
similar approach to generate mAbs against several potential
phosphorylation sites of TDP-43, and here we describe the
characterization of novel rat mAbs 1D3 and 7A9 raised
against phosphorylated S409/410 of TDP-43 as well as the
investigation of S409/410 phosphorylation by immunohis-
tochemistry and biochemistry in a large series of TDP-43
proteinopathies.
Both, ELISA and immunoblot analysis of sarcosyl-insol-
uble protein fractions extracted from FTLD-U brains (with
or without dephosphorylation by alkaline-phosphatase
treatment) demonstrated that mAbs 1D3 and 7A9 have a
high speciWcity to detect phosphorylated TDP-43 species.
By immunohistochemistry using single and double label
methods, we showed that mAbs 1D3 and 7A9 speciWcally
labeled all types of pathologic inclusions, such as NCI,
CGIs, NII, DN previously described with phosphorylation-
independent TDP-43 antibodies [7, 27, 28]. Since FTLD-U
is a highly heterogeneous group with respect to morpholog-
ical subtypes and underlying genetic defects [6, 22, 33], we
expanded our immunohistochemical analysis to a large
series of FTLD-U cases to see whether diVerences in phos-
phorylation might be part of the heterogeneity. However,
we found that phosphorylation of TDP-43 at S409/410 was
a highly consistent Wnding in all diVerent subtypes of
FTLD-U, including familial forms with mutations in GRN
[3, 8], VCP [38] and linkage to chromosome 9p [24, 37].
Moreover, we also demonstrated that phosphorylation of
TDP-43 at S409/410 is also consistently present in abnor-
mal TDP-43 inclusions in ALS and in TDP-43 inclusions
occurring in the setting of other neurodegenerative diseases
such as AD and CBD. Therefore, our data indicate that
phosphorylation at S409/410 occurs within the lesions in all
subgroups of TDP-43 proteinopathies irrespective of the
anatomical and topographical distribution, underlying
genetic defect and clinical presentation, therefore making
these phosphorylation-speciWc TDP-43 antibodies powerful
tools in routine diagnostics of neurodegenerative diseases.
In contrast to phosphorylation-independent TDP-43 anti-
bodies, 1D3 and 7A9 revealed no physiological nuclear
TDP-43 staining by immunohiostochemistry and no detec-
tion of the normal TDP-43 band of »43 kDa by immuno-
blot analysis in cultured cells, mouse and human brain
homogenates (data not shown). These Wndings are in accor-
dance with previous results using diVerent pS409/410 spe-
ciWc antibodies [15, 17] and thereby strongly argue that
phosphorylation of S409/410 seems to be an abnormal
event. However, it cannot be completely excluded that
phosphorylation at S409/410 might occur physiologically
to a minor extent in normal TDP-43 that is below current
detection limits.
By detailed immunoblot analysis of sarcosyl-insoluble
protein fractions extracted from cortical brain areas from
diVerent subgroups of TDP-43 proteinopathies, we consis-
tently found phosphorylated CTFs and full-length TDP-43,
running as bands between 20–25 kDa and bands of
»45 kDa, respectively. In contrast, protein fractions
extracted from spinal cord samples predominantly showed
full-length TDP-43 and weak or absent accumulation of
CTFs, suggesting that protein composition in TDP-43
inclusions in brain and spinal cord neurons might be diVer-
ent. These Wndings are in accordance with a recent publica-
tion using N- and C-terminal speciWc TDP-43 antibodies
[16], which showed that inclusions in cortical regions are
strongly labeled with C-terminal antibodies but not with
N-terminal antibodies, in contrast to inclusions in motor
neurons in spinal cord where similar immunoreactivity was
present with N- and C-terminally speciWc antibodies.
The mechanisms leading to CTF formation are still
unclear. Hasegawa et al. [15] recently claimed that speciWc
banding patterns of phosphorylated CTFs seem to correlate
with underlying FTLD-U subtypes; however, this
observation is based on results on very limited number of
cases (n = 1–2) per FTLD-U subtypes. Nevertheless, in
Fig. 5 Ratio of phosphorylated C-terminal fragments to full-length
TDP-43. Immunoblots of FTLD-U and ALS cases probed with 1D3.
Band intensities of full-length (FL) and C-terminal fragments (CTF) of
TDP-43 were analyzed and the ratio between both values was calcu-
lated. CTF:FL ratios are depicted as a box and whiskers blot that gives
the range of values, with the box being subdivided into the 25 and 75%
quartiles by the median; circles represent outliers, Wlled rhombus
represent the mean
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subtype 2 speciWc antibodies which detect CTFs in a highly
selective manner in the respective subtypes [28, 33], it
appears to be a tempting hypothesis and we therefore per-
formed detailed analysis of the CTFs in our large series of
FTLD-U cases (n = 42). Up to four distinct CTF bands
could be delineated with our phospho-speciWc antibody
1D3, however, the intensities of distinct bands varied con-
siderably between the studied cases within similar FTLD-U
subtypes. While in general there was some overlap with the
banding pattern described in previous studies [15, 17], we
were not able to conWrm or deWne distinct banding patterns
reliably correlating with distinct FTLD-U subtypes or clini-
cal phenotypes in our studied cohort. In addition, the sig-
niWcance of the slightly diVerent band intensities observed
in AD and CBD cases with concomitant TDP-43 pathology
remains unclear and needs to be examined in more detail in
larger series of cases.
In summary, our data show that phosphorylation of
S409/410 of TDP-43 is a highly consistent abnormal event
occurring in all diVerent types of TDP-43 inclusions in the
whole spectrum of familial and sporadic TDP-43 protein-
opathies. Therefore, phosphorylation speciWc antibodies,
such as the described mAbs 1D3 and 7A9, will become
powerful tools not only in the routine diagnostics of neuro-
degenerative diseases, but also in the evaluation of upcom-
ing cellular and animal models for TDP-43 proteinopathies.
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